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Subhadra C. Gunawardana, PhD1 and David W. Piston, PhD1

Background. As our previous publications show, it is feasible to reverse type 1 diabetes (T1D) without insulin in multiple
mouse models, through transplantation of embryonic brown adipose tissue (BAT) in the subcutaneous space. Embryonic
BAT transplants result in rapid and long-lasting euglycemia accompanied by decreased inflammation and regenerated
healthy white adipose tissue, with no detectable increase in insulin. To translate this approach to human patients, it is necessary to establish practical alternatives for embryonic tissue. Adult adipose tissue transplants or BAT-derived stem cell lines
alone fail to reverse T1D. A likely reason is transplant failure resulting from lack of growth factors abundant in embryonic
tissue. Adding growth factors may enable transplants to survive and vascularize as well as stimulate adipogenesis and
decrease inflammation in the surrounding host tissue. Previous data points to insulin like growth factor 1 (IGF-1) as the most
likely candidate. Embryonic BAT abundantly expresses IGF-1, and embryonic BAT transplant recipients exhibit increased
plasma levels of IGF-1. Therefore, we tested the ability of temporary administration of exogenous IGF-1 to enable adult BAT
transplants to correct T1D. Methods. Fresh BAT from healthy adult CB7BL/6 donors were transplanted in the subcutaneous space of hyperglycemic nonobese diabetic recipients. Exogenous IGF-1 was administered daily for a week following
transplant, at 100 µg/kg SC. Results. Adult BAT transplants with IGF-1 supplementation produced rapid long-lasting
euglycemia at a 57% success rate, in contrast with no recovery in the control groups who received adult BAT alone, IGF-1
alone, or no treatment. Conclusions. Temporary supplementation with IGF-1 enables adult BAT transplants to correct
T1D phenotypes independent of insulin, providing a possible route to translate this treatment to human patients.
(Transplantation Direct 2019;5: e500; doi: 10.1097/TXD.0000000000000945. Published online 8 October, 2019.)

T

ype 1 diabetes (T1D) is a serious autoimmune disease
requiring constant glucose management. T1D affects
about 2 million Americans and an estimated 21 million people worldwide, with 40 000 new cases diagnosed each year.
Traditional therapy involves insulin replacement, either
directly or via islet/pancreas transplantation. Besides inconvenience, exogenous insulin administration carries the risk
of hypoglycemia unawareness, a potentially fatal outcome.
Pancreas transplantation involves the obvious limitations of
invasive surgery and life-long immuno-suppression, while islet
transplantation is also limited by availability of donor tissue,
need for immuno-suppression, and return to insulin dependence over the long term.1-5 Despite continuous refinement

through the past decades, effective solutions for these basic
limitations have not been found. A comprehensive review
of the safety and efficacy of commonly used type 2 diabetes
drugs as add-on therapies to insulin in T1D concluded that
their efficacy was minimal or modest, and such add-on therapy was not generally recommended for T1D.6 Thus, there is
an ongoing need for better therapies for T1D.
The ultimate goal in treating T1D is to restore glucose
homeostasis. Our work has shown that glucose homeostasis can be achieved without insulin, using subcutaneously
placed embryonic brown adipose tissue (BAT) transplants.7,8
In both streptozotocin-diabetic and autoimmune-induced
nonobese diabetic (NOD) mice, BAT transplants reestablish
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normoglycemia independent of insulin. T1D is associated with
inflammation both generalized and in white adipose tissue
(WAT), and loss of WAT.9-11 Embryonic BAT transplants lead
to remarkable recovery of WAT, decreased inflammation, and
reversal of diabetes.7,8 Euglycemia correlates with suppression
of glucagon, and progressive increases in plasma adiponectin,
insulin like growth factor 1 (IGF-1), and sometimes leptin.
Thus, it appears that a combination alternate hormones arising from BAT transplant and/or regenerated WAT establishes
a new physiological equilibrium, compensating for endocrine
pancreas.
While this technique is proven effective in long-term reversal of T1D in mice, transplantation of embryonic tissue is
not a practical solution for human patients. The goal of the
current study was to implement appropriate modifications to
reproduce the results with adult BAT transplants, a plausible
alternative to embryonic BAT in clinical settings.
The presence of BAT in healthy human adults and its
importance in combating metabolic disease is demonstrated
in recent literature.12-14 While several studies show the ability
of adult BAT and WAT transplants to alleviate diabetes and
obesity, and to improve metabolism,13-19 complete reversal of
insulin-dependent diabetes has not been achieved as it is with
embryonic BAT transplants. According our own experience,
transplantation of adult BAT or WAT alone fails to reverse
T1D. Certain growth factors are abundant in embryonic tissue, and may enable embryonic BAT transplants to survive
and vascularize in the recipients’ subcutaneous space as well
as stimulate adipogenesis and decrease inflammation in the
surrounding host tissue. Plausible candidate growth factors
include IGF-1, fibroblast growth factor 21, and adiponectin,
all of which are highly expressed in embryonic tissue, possess
adipogenic and anti-inflammatory properties, and can mediate insulin-independent glucose transport and metabolism in
peripheral tissues.20-40
Our data strongly point to donor-origin IGF-1 as a critical mediator in the early changes following BAT transplant.7,8
Reversal of diabetes occurs only with donor embryonic BAT
from healthy C57BL/6 mice, and not with donor BAT from
NOD mice who are deficient of IGF-1. IGF-1 levels in recipients’ plasma significantly increase within a week of BAT
transplant placement, and progressively increase thereafter parallel to weight gain and WAT regeneration, in negative correlation with proinflammatory cytokines.7,8 IGF-1 is
abundantly expressed in freshly isolated BAT from C57BL/6
embryos.7 Newly formed WAT in NOD transplant recipients
continues to express IGF-1 for several months posttransplant,
in contrast to little or no expression in control animals.7,8 It
is noteworthy that only 50% of embryonic BAT transplants
result in long-term euglycemia, and the ones that fail lack this
increase of IGF-1 but instead show a progressive decrease of
IGF-1.7 Thus, it seems that the presence of IGF-1 during the
early stage of BAT transplant is critical for establishment of
the new equilibrium of alternate hormones. Adipogenic and
anti-inflammatory properties of IGF-1 might enable the regeneration of healthy WAT, which in turn could secrete other
insulin-mimetic adipokines to compensate for the function of
insulin. IGF-1 may also have direct actions on glucose lowering through insulin-independent glucose uptake via GLUT1
and GLUT3 transporters.34-36,40 Pharmacological inhibition
of the insulin receptor in euglycemic BAT transplant recipients partially impairs their glucose tolerance,8 suggesting

the occupation of insulin receptor by a noninsulin hormone.
IGF-1 is a candidate here as well, due to the structural similarity of insulin and IGF-1 receptors.41,42
Based on the aforementioned data, we hypothesize that the
failure of adult BAT transplants to reverse T1D is due to the
lack of IGF-1, which may be corrected by supplementation
with exogenous IGF-1 during the early stages. To test this
hypothesis, we performed experiments to determine whether
adult BAT transplants temporarily supplemented with IGF-1
can produce euglycemia in NOD mice with autoimmuneinduced diabetes.

MATERIALS AND METHODS
Experimental Design
All animal studies were approved by the Washington
University Institutional Animal Care and Use Committee,
under the Animal Welfare Assurance # A-3381-01, and
Protocol # 20150121. BAT transplants were performed as
described previously,7,8 on female NOD mice (Jackson labs,
stock # 001976) 4–6 months old. Donor adipose tissue came
from healthy young adult C57BL/6 females (Jackson labs,
stock #000664) 1–2 months old. Experiments were performed on NOD mice determined diabetic by a repeated nonfasting blood glucose level over 200 mg/dL. The test group
was provided with exogenous IGF-1 for the first 7 days following BAT transplant (100 µg/kg/day SC), in the lower end
of the dosage range found in the literature on IGF-1 administration to mice and rats for various purposes. Control groups
included diabetic mice who received adult BAT transplants
alone, IGF-1 injections alone, or saline injections alone. Body
weight was recorded, and non-fasting blood samples were collected before and at regular intervals after treatment, that is,
every week for the first month following treatment, and every
month thereafter. Metabolic parameters, such as blood glucose, insulin, glucagon, adiponectin, and IGF-1, were measured from transplant and control groups at regular intervals.
Glucose tolerance tests were performed on representative
euglycemic transplant recipients in comparison with normal
and diabetic controls. Depending on the group and glycemic
status, mice were euthanized at different time points after
1 month, and tissues were collected postmortem. The presence of insulin and glucagon in the pancreas, and the presence of insulin and IGF-1 in adipose tissue, were verified with
immunofluorescence.
Isolation of Donor Tissue
Donor mice are anesthetized with ketamine/xylazine
(200/40 mg/kg IP). Following aseptic preparation, interscapular adipose tissue is exposed through a dorsal midline skin
incision. WAT is gently removed, and the BAT is dissected
out. The mouse is immediately killed by cervical dislocation
while under anesthesia. Freshly isolated BAT is placed in sterile ice-cold HBSS, and transplanted into recipients as quickly
as possible.
Transplantation
Freshly isolated adult BAT is transplanted in the subcutaneous space of diabetic recipients. Following general anesthesia
and aseptic preparation, a small (2–4 mm) incision is made in
the skin of the dorsal body surface caudal to the endogenous
BAT. A subcutaneous pocket is made by blunt dissection using
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a blunt-ended micro spatula. Donor tissue is introduced into
the pocket with Dumont forceps and pushed in with bluntended micro spatula. The incision is closed by gentle pressure
with hemostats alone, or with 1–2 simple interrupted sutures
as necessary with 5–0 nonabsorbable sutures. One to 2 lobes
of adult BAT are introduced into each recipient. Surgeries are
performed under general anesthesia with ketamine/xylazine
(100/20 mg/kg) IP, and postoperative analgesia is provided
with ketoprofen 5 mg/kg/day SC as necessary. Sutures are
removed in 7–10 days postop.
Metabolic Parameters
Blood samples were collected from a tail-nick under isoflurane/oxygen anesthesia, for measurement of glucose, insulin,
and other hormones. Basal non-fasting blood samples were
collected before treatment, at weekly intervals after treatment for the first month, and at monthly intervals thereafter. Plasma samples were analyzed for insulin, glucagon,
adiponectin, and IGF-1. Intra-peritoneal glucose tolerance
tests were performed on successful transplant recipients at 5
months posttransplant, in comparison with normal and diabetic controls. Intra-peritoneal glucose tolerance test involved
tail-nick blood glucose measurements from 6-h fasted mice
before (0 min) and 15, 30, 60, and 120 minutes after intraperitoneal injection of sterile glucose (Sigma) (1 g/kg body weight)
under isoflurane/oxygen anesthesia.
Postmortem Tissue Collection
Mice were euthanized at different time points between 1
and 12 months after procedure, and adipose tissue and pancreas were retrieved for histology. The whole pancreas and the
adipose tissue from the subcutaneous space of the dorsal body
surface were collected, and the tissues were preserved in 70%
ethanol for histological analysis.
Statistical Analysis
Groups were compared 2 at a time as denoted in each
experiment, using Students homoscedastic t test. Values are
expressed as mean ± SEM. Numbers (n) for each group and
statistical probabilities (P) for each comparison are specified
in the Results section, figures, or figure legends.

RESULTS
NOD female mice develop spontaneous diabetes after 12
weeks of age. Diabetic mice have basal non-fasting blood glucose over 200 mg/dL, which quickly rises to 600 mg/dL within
weeks. If untreated, they die or require euthanasia soon after
the onset of diabetes. Successful BAT transplant recipients are
defined as those diabetic mice whose basal non-fasting blood
glucose levels decreased below 180 mg/dL and stayed below
180 mg/dL for at least 2 months following transplant, with
no other clinical signs of diabetes or metabolic abnormalities.
Adult BAT transplants temporarily supplemented with
IGF-1 produced rapid and long-lasting euglycemia, similar to
the results previously observed with embryonic BAT transplants (Figure 1). Out of a total of 21 NOD mice that received
adult BAT transplants with IGF-1 supplementation daily for
the first week posttransplant, 12 recovered from diabetes (successful transplants) while 9 did not (failed transplants), providing a 57% success rate. The successful transplant recipients
achieved euglycemia within a week of treatment (Figure 1A).
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Of the successful transplant group, 9 mice remained euglycemic until euthanasia at different endpoints ranging from
6 to 12 months, while 3 reverted to diabetes at months 3
and 7. Euglycemic transplant recipients also showed normal
glucose tolerance comparable to normal nondiabetic controls (Figure 1B). Recovery from diabetes was not generally
observed in the control groups that received adult BAT transplants alone, IGF-1 injections alone, or saline injections alone
(Figure 1A). Due to increasing severity of clinical signs, these
animals had to be euthanized at different time points within
3 months from development of hyperglycemia. One mouse
from the group treated with IGF-1 injections alone showed
euglycemia that lasted for 3 months post procedure. This
mouse also showed abnormalities, such as excessive weight
gain and organ enlargement, and therefore was removed from
the study. One mouse from the control group receiving adult
BAT transplants alone also showed some resistance to diabetes, where severe hyperglycemia did not develop immediately,
and basal glucose levels stayed between 190 and 200 mg/dL
for 5 weeks. While this caused an increase in the error bars in
this group, the overall trend remained unchanged.
As previously reported with embryonic BAT transplants,
the results are independent of insulin, as indicated by progressively decreasing levels of plasma insulin and the absence
of insulin immunofluorescence in the pancreas postmortem
(Figures 2A and 3). All groups show a progressive decline of
plasma insulin as characteristic with NOD mice, compared
with normal nondiabetic controls at 2457.4 ± 571.5 pg/mL.
Pancreatic sections in diabetic control mice have little or
no immuno-staining for insulin, while successful transplant
recipients who remained euglycemic for 10 months show
none at all (Figure 3, left panels). As diabetes progresses in
NOD mice, there is a general decline in islet number and
disruption of islet structure. Figure 3B and C (left panels)
represent some of the remaining intact islets, to demonstrate
the visible absence of insulin immunostaining. While acinar
tissue and blood vessels can show some green autofluorescence, this is distinct from the actual immunofluorescence
for insulin as seen in the control pancreas. As is characteristic in NOD mice, many islets in the diabetic control group
show immune cell infiltration and disruption of islet structure upon H&E staining (Figure 3B, Right). Such cell infiltration was not evident in successful transplant recipients
(Figure 3C, Right), presumably due to a widespread decrease
of inflammation.
Euglycemia is also accompanied by suppression of glucagon
(Figure 2B) albeit to a lesser degree than previously observed
with embryonic BAT transplants. Suppression of glucagon
following transplants is further confirmed by the absence of
glucagon immunostaining in the pancreas from successful
transplant recipients as opposed to normal and diabetic controls (Figure 3, Left panels).
Euglycemia is also associated with increases in extra-pancreatic insulin-mimetic hormones, which may compensate
for the lack of insulin. Successful transplant recipients show
consistently higher levels of plasma adiponectin and IGF-1
compared with control groups (Figure 4). Euglycemia without
insulin occurs only in those situations where suppression of
glucagon is accompanied by a simultaneous increase of IGF-1
and adiponectin. Insulin-independence is further confirmed by
the lack of insulin-immunostaining in the transplant or surrounding adipose tissue.
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FIGURE 1. Glucose homeostasis in NOD mice following aBAT TP supplemented with IGF-1. A, Non-fasting blood glucose levels before and

at weekly or monthly intervals after placement of aBAT TPs followed by supplementation with IGF-1 (100 µg/kg SC) for 1 wk, in comparison with
control groups. Successful transplant recipients (closed circles) achieve and maintain euglycemia within a wk from transplant, while the control
groups and failed transplants (open circles) become progressively hyperglycemic. Control groups included diabetic mice treated with aBAT TPs
alone (closed squares), IGF-1 injections alone (open squares), or saline injections alone (closed triangles). *P < 0.004 when each posttransplant
time point of the successful transplant group is compared with corresponding time points of other groups, or their own pretransplant values.
Normal nondiabetic controls: 132.4 ± 11.2 mg/dL. B, Intra-peritoneal glucose tolerance test in 6-h-fasted mice. n = 3 for each group *P < 0.002
when the diabetic control group is compared with successful transplant group or normal control. aBAT TP, adult BAT transplant; BAT, brown
adipose tissue; IGF-1, insulin like growth factor 1; NOD, non obese diabetic.

Although IGF-1 is not generally expressed in WAT, euglycemia following embryonic BAT transplants is associated
with increasing expression of IGF-1 in newly formed WAT.7,8
Similarly, current data show expression of IGF-1 in the WAT
of successful transplant recipients who became euglycemic,
compared with little or no expression observed in failed
transplants and controls (Figure 5A). Again, even though
adipocytes normally show some green autofluoresence, this
is distinguishable from the bright immunofluorescence in
response to the IGF-1 expression observed in successful transplant recipients. IGF-1 expression in adipose tissue is observed
only in successful transplant recipients, and some areas show
greater expression than others. Figure 5A top left shows IGF-1
expression over a large area at low magnification, while the
top right image shows a brighter area of expression at higher
magnification. While adult BAT lacks the IGF-1 expression
normally abundant in embryonic BAT (Figure 5B), temporary
supplementation with exogenous IGF-1 seems to enable the
survival and function of adult BAT transplants. This leads to
subsequent expression of IGF-1 in adipose tissue, increased
secretion of beneficial adipokines, and insulin-independent
glucose homeostasis.

DISCUSSION
BAT is well known to improve metabolic regulation and
alleviate obesity, effects generally attributed to its thermogenic
properties.12-14 However, all of its beneficial effects cannot be
explained by thermogenesis alone, particularly considering that
reversal of T1D following BAT transplants is associated with a
gain of WAT rather than loss. BAT is different from WAT in its
developmental origin as well as in function and cellular composition. While WAT originates from mesodermal stem cells,
BAT originates from dermatomyotomal precursor cells as does
skeletal muscle, and is interchangeable with skeletal muscle
during development. Unlike WAT which stores and accumulates fat, BAT is geared towards metabolism of fat and generation of heat, aided by large amounts of mitochondria and
uncoupling protein 1. BAT shows greater vascularization and
innervation compared with WAT, with small multilocular lipid
droplets in brown adipocytes as opposed to the large unilocular droplets found in white adipocytes. WAT can be harmful
under certain circumstances such as insulin-resistant obesity,
where inflammation, hypertrophy, and necrosis of adipose tissue may cause/exacerbate the metabolic dysfunction. However,

© 2019 Wolters Kluwer
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FIGURE 2. Changes to insulin and glucagon following aBAT TP. A, Plasma insulin levels at monthly intervals in the transplant group in

comparison with control groups. Normal nondiabetic controls: 2457.4 ± 571.5 pg/mL. B, Plasma levels of glucagon before and at monthly
intervals following transplant, in comparison with control groups. *P < 0.004 when the successful transplant group is compared with diabetic
control group at the 2-mo time point. Normal nondiabetic controls: 33.6 ± 6.8 pg/mL. aBAT TP, adult BAT transplant; BAT, brown adipose tissue;
IGF-1, insulin like growth factor 1.

situations where BAT and WAT functionally complement each
other can produce great benefits including correction of metabolic disease, as evidenced by the insulin-independent reversal
of diabetes following BAT-transplants.
As demonstrated in our previous publications, euglycemia
following embryonic BAT transplants is associated with generalized decrease of inflammation, regeneration of healthy
WAT, suppression of glucagon, and progressive increases of
nonpancreatic insulin-mimetic hormones primarily of adipose
tissue origin.7,8 It is noteworthy that these results occur only
with embryonic BAT. Adult BAT transplants or BAT-derived
stem cell lines alone fail to produce insulin-independent euglycemia, as do other embryonic tissue types. Therefore properties of both BAT and embryonic tissue seem to be critical.
T1D is associated with inflammation of WAT and loss of
healthy functional WAT.11,15 The thermogenicity and increased
metabolism characteristic of BAT, and the adipogenic and
anti-inflammatory properties unique to embryonic tissue,
may together improve the structure and function of WAT in
diabetic animals, enabling it to secrete beneficial adipokines
that compensate for the lack of insulin. The inability of adult

BAT transplants to produce euglycemia is attributable to the
lack of such adipogenic and anti-inflammatory growth factors, which are abundantly expressed in embryonic tissue. We
hypothesized that exogenous administration of growth factors would correct this problem. Previous data suggest IGF-1
as a likely candidate growth factor.7
The current results confirm a critical role for IGF-1 in insulin-independent euglycemia brought about by BAT transplants.
Insulin independence is confirmed by progressively decreasing
plasma insulin levels comparable with the diabetic controls,
and lack of insulin immunostaining either in pancreatic islets
or in adipose tissue. It is noteworthy that IGF-1 alone or
adult BAT transplants alone cannot achieve euglycemia, and
the presence of both is required. As previously observed with
embryonic BAT transplants, adult BAT transplants temporarily supplemented with IGF-1 result in rapid and long-lasting
euglycemia in diabetic mice. Euglycemia is accompanied by
suppression of glucagon, and increased levels of adiponectin
and IGF-1 in plasma. The success rate in reversing diabetes is
50%–60% in both situations. Documenting the exact reasons
for lack of a 100% success rate is beyond the scope of this
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FIGURE 3. Pancreatic sections immuno-stained for insulin with Alexa-Fluor 488 (green), and for glucagon with Alexa-Fluor 594 (red), with
the right column showing corresponding H&E stained sections. A, Normal nondiabetic control. B, Diabetic control treated with saline alone. C,
Successful transplant recipient euglycemic at 10-mo .

study, considering the many variables and unknowns involved
in a treatment that works through altering the whole body
metabolism and establishing a new physiological equilibrium.
Variables that may be tested and adjusted in a larger scale
study include the age of donors, time from isolation of donor
tissue to transplantation, site of transplantation, dosage of
IGF-1, duration of IGF-1 administration, and possible combination with additional growth factors or anti-inflammatory
agents. One consistent observation from all our experiments
was that euglycemia occurs only when there is a simultaneous

increase in plasma levels of IGF-1 and adiponectin together
with suppression of glucagon. Control and failed transplant
animals, either adult or embryonic, lack this particular hormonal profile, emphasizing the importance of alternate hormones compensating for the lack of insulin.
The importance of these extra-pancreatic hormones in glucose homeostasis is well documented. Both IGF-1 and adiponectin have beneficial effects on glucose regulation, including
some insulin independent mechanisms.43-50 Metabolic disease
states such as diabetes, obesity, and insulin resistance are

© 2019 Wolters Kluwer
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FIGURE 4. Euglycemia is associated with an increase of extra-pancreatic hormones: plasma levels of IGF-1 (A) and adiponectin (B) at monthly

intervals following transplant, in comparison with control groups. Successful transplant recipients (closed circles) show a persistent increase in
both hormones in contrast to a decrease observed in the other groups. *P < 0.05 when the successful transplant group is compared with other
groups at the 1 mo time point. Normal nondiabetic controls: 16.6 ± 2.5 µg/mL adiponectin and 205.4 ± 61.8 ng/mL IGF-1. aBAT TP, adult BAT
transplant; IGF-1, insulin like growth factor 1.

associated with decreased plasma levels of both hormones.51-55
Monotherapy with IGF-1 or adiponectin are reported to alleviate diabetes and insulin resistance,43-50,56 even though such
therapies are limited by side effects including hypoglycemia,
tachycardia, edema, facial pain, or paralysis etc44,48,56 Side
effects are unlikely with BAT transplants, since the increases in
plasma adipokine levels are not supraphysiological, merely a
return to normal from the decreased levels in T1D.
Recent literature shows the importance of glucagon in the
pathogenesis of diabetes.57 The suppression of glucagon normally produced by glucose and insulin is lost in diabetes, and
the resultant hyperglucagonemia exacerbates hyperglycemia.
Persistent hyperglucagonemia, rather than insulin deficiency,
has even been proposed to be the primary driver of hyperglycemia in diabetes. Inhibition of glucagon secretion or glucagon action has been shown to restore euglycemia in diabetic

animals, even in the absence of insulin. Thus, suppression
of glucagon by itself is a proposed therapeutic approach for
diabetes.57 However, pharmacological agents for direct suppression glucagon secretion are not available, and glucagon
receptor antagonists are limited by side effects and possible
malignant transformation of α cells.58 The physiological equilibrium produced by BAT transplants involving a combination
of endogenous insulin-mimetic hormones and suppression of
glucagon may well be an alternative long-term solution.
In our previous studies, streptozotocin-treated C57BL/6
mice became euglycemic following BAT transplants, and
showed a significant and progressive increase in leptin.8 In
diabetic NOD recipients, we did not observe a significant
increase of leptin, either with embryonic or adult BAT transplants. Leptin may not be a major player in BAT transplantmediated glucose regulation, considering that BAT transplants
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FIGURE 5. IGF-1 expression in adipose tissue: adipose tissue sections immuno-stained for IGF-1 with Alexa-Fluor 488 (green). A, NOD mice:
IGF-1 is expressed in the adipose tissue of successful transplant recipients euglycemic at 10 mo, but not in failed transplants or controls. B,
C57BL/6 mice: IGF-1 is expressed in freshly isolated embryonic BAT but not in adult BAT. BAT, brown adipose tissue; IGF-1, insulin like growth
factor 1; NOD, non obese diabetic.

© 2019 Wolters Kluwer

are also associated with decreased inflammation, recovery of
WAT, and a moderate weight gain.
Thus, the beneficial effects of embryonic BAT transplants
could generally be reproduced by temporary supplementation of adult BAT transplants with exogenous IGF-1. While
the tolerance of embryonic BAT allografts is attributable to
the immune-privileged nature of embryonic tissue, we found
that adult BAT transplants were also well tolerated. Literature
shows that, unlike with other organs, rejection is not common with adipose tissue transplants.13-19 Transplanted adult
BAT was identifiable by naked eye at 7 months posttransplant
in some recipients, at considerably reduced size. In contrast,
transplanted embryonic BAT soon becomes indistinguishable
from surrounding host tissue and cannot be detected microscopically.7 Development of euglycemia does not seem to
require the presence of intact transplanted tissue, but rather,
the positive changes imparted to the host adipose tissue such
as decrease of inflammation, proliferation of new healthy
WAT cells, and secretion of insulin-mimetic adipokines.7
The current results demonstrate the feasibility of establishing long-term euglycemia in diabetic mice using adult BAT
transplants, and are consistent with a model where beneficial
insulin-mimetic hormones from adipose tissue maintain insulin-independent glucose homeostasis. This effect appears to
occur partly through glucagon suppression and partly through
direct effects on glucose uptake and metabolism. While the
specific underlying mechanisms remain poorly understood, we
can make some speculations based on what has been learned
so far. Current data suggest that donor-origin IGF-1 is essential for the survival and function of BAT transplants in the
early stages. This possibility can be tested by deleting IGF-1
from embryonic BAT transplants and verifying their ability
to produce euglycemia. Successful BAT transplants establish
a physiological equilibrium with increased adipokines and
decreased glucagon, maintaining euglyemia in the absence of
insulin. Preliminary data with BAT-conditioned media suggest that secreted peptides from BAT transplant may suppress
glucagon secretion from pancreatic islets and stimulate IGF-1
secretion from liver and/or adipocytes. Studies are underway
to identify and purify such messenger molecules.
Adult BAT transplants temporarily supplemented with
IGF-1 is a plausible therapeutic approach transferable to
human patients, that bypasses the complications associated
with insulin replacement. Side effects are less likely since this
treatment does not involve long-term administration of any
exogenous compound, and glucose regulation is brought
about by a physiological equilibrium of endogenous insulinmimetic hormones. While concerns remain regarding the
sources and availability of donor adult BAT, possible solutions include the implantation of BAT-derived stem cells or
expansion of endogenous BAT with pharmacological agents
such as beta-3 adrenergic agonists,59,60 together with temporary administration of IGF-1.
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